CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational.

Slides:



Advertisements
Similar presentations
High-Frequency Spinal Cord Stimulation Therapy in Failed Back Surgery Syndrome Patients with Predominant Back Pain Adnan Al-Kaisy1, Jean-Pierre Van Buyten2,
Advertisements

London Bridge Hospital Orientation
Process Study 24-Month Results October 1, 2008 (abridged)
PROCESS vs. WA State SCS Study A Comparison of Study Design, Patient Population, and Outcomes August 29,2007.
Neurostimulation For Complex Regional Pain Syndrome Literature Review Summary.
Martha J. Morrell MD NeuroPace, Inc.
SCS: Indications Contraindications Medical Necessity
 Minimally invasive & reversible treatment option for chronic pain  Neuropathic pain  Few previous case reports in severe abdominal / pelvic visceral.
Efficacy of Cervical Spinal Cord Stimulation for Chronic Pain
C. Perruchoud, E. Buchser, A Durrer, B. Rutschmann, M. Rosato1,2, N
Katie Rousseau Erich Richter, M.D. LSU Health Sciences Center, New Orleans.
Mapping of Posture-Dependent Shifts in Paresthesia during Spinal Cord Stimulation (SCS) Cong Yu MD 1, Thomas Yang MD 1, Shaun Kondamuri MD 2, Satish Dasari.
What is Pain? Conceptualizing Chronic Pain Tissue Disruption Functional Disruption Environment and Treatment Expression of Pain.
N. Camden Kneeland, M.D., D.A.B.A.
Successful Treatment of Low Back Pain with a Novel Neuromodulation Device Iris Smet, MD 1 Jean-Pierre Van Buyten, MD 1 Adnan Al-Kaisy MB ChB FRCA 2 1 AZ.
NM AA_DEC2014 Long-Term Back Pain Relief with Precision Spectra SCS and 32-Contact Anatomically-Based Programming Salim Hayek MD PhD 1, Elias Veizi.
Spinal Cord Stimulators. FDA-approved therapy to treat chronic pain of the trunk and/or limbs Used to treat patients with neuropathic pain SCS is considered.
InFUSE ™ Bone Graft / LT-CAGE ™ Lumbar Tapered Fusion Device IDE Clinical Results G Hallett H. Mathews, M.D. Richmond, Virginia.
NEUROPATHIC PAIN – OPTIMIZING PATIENT OUTCOME WITH COMBINATION THERAPY.
Ranjith Babu, MS 1 Jonathan Choi, MD 1 Adam Back, MD 1 Vijay Agarwal, MD 1 Matthew Hazzard, MD 1 Beatrice Ugiliweneza, MSPH PhD 2 Chirag G. Patil, MD MS.
Cost-effectiveness of Spinal Cord Stimulation for Failed Back Surgery Syndrome Using Rechargeable Equipment Richard B. North, MD 1  Rod S. Taylor, PhD.
Spinal Cord Stimulators in Neuropathic Pain. Introduction Chronic pain is very common Immense physical, psychological, societal impact Financial burden.
Effects of hydrotherapy in Knee Osteoarthritis
PERIPHERAL NERVE FIELD STIMULATION: MIRAGE OR REALITY? Dr Paul Verrills Interventional Pain Physician MBBS FAFMM MPainMed FIPP Metro Spinal Clinic, Australia.
Overview of Neurostimulation
Neuromodulation for Headache & Craniofacial Pain: 50 Consecutive Cases Paul Verrills MD, David Vivian MD, Bruce Mitchell MD and Adele Barnard PhD Metro.
BASIC CONCEPT OF SRAMBLER THERAPY IN THE DEVELOPMENT OF SCRAMBLER THERAPY ARTIFICIAL NEURONS WERE DEVELOPED TO TRANSMIT VIA.
Leadership Through Innovation Tm
Spinal Cord Stimulation and Pain Relief in Painful Diabetic Peripheral Neuropathy: A Prospective Two-Center Randomized Controlled Trial Featured Article:
INVASIVE PAIN MANAGEMENT METHODS FOR CHRONIC NONCANCER PAIN
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Design: A randomized, prospective, double-blind cohort followed for 16 weeks RenehaVis Original Study 50 DMW 50 HMW 50 LMW 50 Placebo.
PHARMARCOLOGICAL FUNCTIONAL MRI FOR NEUROPATHIC PAIN: EVALUATING ANALGESIC EFFICACY.
Position-Adaptive Stimulation and Improved Pain Relief: Results of the RestoreSensor Study Lynn Webster, MD Lifetree Clinical Research and Pain Clinic,
Efficacy and Tolerability of the Diclofenac Epolamine Patch in the Treatment of Minor Soft Tissue Injury W Carr, P Beks, C Jones, S Rovati, M Magelli,
Costs of Neurostimulation Can We Afford The Therapy in 2020? Krishna Kumar MBBS MS FRCS(C) Member Ord. of Canada, Saskatchewan Ord. of Merit Clinical Professor.
Diagnosis and Management of Diabetic Neuropathies Part 4
TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION IN DIABETIC NEUROPATHY Sanjay Kalra, Bharti Kalra, Bharti Hospital, Karnal INDIA
Quality of life results from a Phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer Taroh.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Evidence Based Medicine for SCS
Advanced Interventional Options for Chronic Pain October 9, 2105 Daniel Kwon, MD.
How To Design a Clinical Trial
UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
SCS and IDDS: Patient Selection
Anders Mellgren, MD, PhD, FACS, FASCRS Clinical Professor of Surgery Division of Colon & Rectal Surgery University of Minnesota Director, Pelvic Floor.
: Intermittent Neurogenic Claudication Aperius ® Percutaneous Interspinous Spacer F. Collignon, P. Fransen, D Morelli, N. Craig, J. Van Meirhaeghe For.
CDRH Advisory Committee Meeting: Orthopedic and Rehabilitation Devices Panel November 20, 2002 INDEPENDENCE™ iBOT™ 3000 Mobility System Independence Technology.
Spinal Cord Stimulators: Typical Positioning and Postsurgical Complications Elcin Zan, M.D. Kubra N. Kurt, M.S. Paul J. Christo, M.D. David M. Yousem,
mild Decompression for the Treatment of Lumbar Spinal Stenosis
Spinal Cord Stimulation
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
The Emergence of Therapeutic Neurostimulation: Reducing Barriers to Innovation and Growth John Reppas MD- PhD Director of Public Policy American Society.
SANTE: Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy Professor Ley Sander MD PhD FRCP.
Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.
FreeVis LASIK Zentrum Universitätsklinikum Mannheim
How To Design a Clinical Trial
Spinal Cord Stimulation (SCS): A proven surgical option for chronic pain Jeffrey M. Epstein, M.D. Babylon, NY.
Prospective study to evaluate the effectiveness of DRG stimulation
The efficiency of neuropathic pain removing using different methods of neurostimulation N.A. Sapon Restorative Neurosurgery Department, Romodanov Neurosurgery.
Quality of Life Assessment
37th International Conference of the IEEE Engineering in Medicine and Biology Milan, Italy, August 2015 Intense Therapy Ultrasound (ITU) for the Treatment.
1- Guided Therapy Systems, Mesa, AZ, 2-The Core Institute, Phoenix, AZ
Jean-Pierre Van Buyten, MD  Journal of Pain and Symptom Management 
Hallett H. Mathews, M.D. Richmond, Virginia
Supported in part by Arkansas Blue Cross and Blue Shield
Outcomes in SCS Trials Ali Rezai MD.
Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain
Yoga treatment for chronic non-specific low back pain
Presentation transcript:

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Effects of Spinal Cord Stimulation of the Dorsal Root Ganglion (DRG) in the Treatment of Chronic, Intractable Pain: Long-Term Results from Two Prospective Clinical Trials L Liem, M.D. F Huygen, M.D., Ph.D Marc Russo, M.D. JP Van Buyten, M.D. I Smet, M.D. Paul Verrills, M.D. Professor Michael Cousins, M.D. Raj Sundaraj, M.D. Charles Brooker, M.D. NANS 2012

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Disclosures Philips Boston Scientific Spinal Modulation Caution: The Spinal Modulation Axium™ Spinal Cord Stimulator System is currently an investigational device in the United States and is not approved for use in the United States.

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Specialized delivery system for efficient access to the foramen Small, flexible leads have been designed specifically for stimulation of the DRG Small, non- rechargeable neurostimulator designed to complement the lead and system Conventional Lead DRG Lead Spinal Cord Stimulation Targeting the Dorsal Root Ganglion

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Clinical Study Design 2 prospective clinical trials Sites in Europe and Australia enrolled subjects N=32 subjects implanted with Spinal Modulation Axium™ Spinal Cord Stimulator System Primary and secondary outcome measures captured Two (2) on-off periods to demonstrate “rebound” pain 3-30 days Stimulation turned off Trial 1 week Screen Fail Baseline 4 weeks 1 year Baseline Implant Trial Exit 1 week off 1 week off yes no 6 months 3 months 8 weeks* Stimulation turned off Success?

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Study Outcomes Primary Efficacy was determined by Visual Analog Scale (VAS)  Both overall pain and regional (“segmented”) VAS scores were collected over time based upon primary, secondary and/or tertiary areas of pain Safety was evaluated by collecting adverse events during the course of the trial Secondary Health Related Quality of Life (HR-QoL) – EQ-5D Profile of Mood States (POMS) Brief Pain Inventory (BPI) Subject Satisfaction Paresthesia Intensity with Changes in Bodily Position

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Subject Diagnoses Diagnosis#INS FBSS9 CRPS8 Post-surgical neuropathic pain conditions7 Radicular pain8 Total Implants32

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. PRIMARY OUTCOMES Visual Analog Scores (VAS)

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Primary Outcomes – Overall Pain Relief 60% reduction at 12 months VAS (mm) n=32 n=30n=24 n=17

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. 66% reduction at 12 months * Diagnoses include CRPS, Post-Surgical Pain, FBSS, Radicular Pain Primary Outcomes – Leg Pain* VAS (mm) n=25 n=24n=19n=22n=19n=13

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. 82% reduction at 12 months * Diagnoses include CRPS, Post-Surgical Pain, FBSS Primary Outcomes – Foot Pain* VAS (mm) n=13 n=9n=12n=10n=6

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. 1 week No Stim 1 week No Stim Assessing Rebound Pain after Stimulation is Turned Off

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Less Lead Migration than traditional SCS Stimulation leads for SCS of the DRG reported <3% migration rates. Traditional SCS (PROCESS trial) reports migration rate of 10%. 1 1 Kumar, et al, Pain, 2007

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. SECONDARY OUTCOMES

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Limited Changes in Paresthesia Intensity N=22

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Painful Regions Paresthesia Therapeutic targeting: Specific & Painful Regions Example representations of painful regions and areas of therapeutic coverage. Paresthesias could be generated in both discrete and broad coverage zones. Most paresthesias were generated over the painful regions with little extraneous paresthesias in non-painful regions.

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. EQ-5D: Independent Outcomes Baseline6 months

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Brief Pain Inventory- Overall Outcomes Significant improvements in both Pain Interference and Pain Severity measures (*p<0.05)

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Profile of Mood States: POMS Outcomes

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. Conclusions Clinical data from European and Australia clinical trials show that the Axium™ SCS System can provide significant long-term pain relief in CRPS, Post-Surgical Neuropathies, and FBSS Body positions (standing versus supine) did not affect the intensity of paresthesia and is stable over 12 months Stimulation can be isolated to specific anatomical regions such as the foot and leg Therapy is stable long term with less than 3% lead migration Secondary measures of quality of life, mood and activity are all improved complimenting the reductions in pain.

CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational use only. THANK YOU